NCT02971956

Pembrolizumab in Refractory Advanced Esophageal Cancer

A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 49 (actual)
• Sponsor: Dana-Farber Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This research study is studying a targeted therapy as a possible treatment for advanced esophageal cancer. The study intervention involved in this study is: -Pembrolizumab

Detailed description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The FDA (the U.S. Food and Drug Administration) has not approved Pembrolizumab for the participant specific disease but it has been approved for other uses. Pembrolizumab, also known as KEYTRUDA or MK-3475, is approved in the USA and several other countries to treat other types of diseases. The goal of this research study is to -Evaluate the safety and efficacy of pembrolizumab in participants with advanced esophageal cancer that have not responded to standard treatment.

Conditions

• Esophageal Cancer
• Squamous Cell Esophagus Cancer
• Adenocarcinoma Esophagus

Interventions

Type	Name	Description
DRUG	Pembrolizumab	Immune checkpoint inhibitor

Timeline

• Start date: 2017-01-18
• Primary completion: 2019-07-23
• Completion: 2020-05-13
• First posted: 2016-11-23
• Last updated: 2023-09-21
• Results posted: 2022-04-08

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study